Business Wire

Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting

TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its ...
Healthline

Liver Cancer Tumor Markers: Their Role in Diagnosis and Treatment

Doctors often monitor tumor markers in the blood to help diagnose and treat liver cancer. Alpha-fetoprotein (AFP) is the most common tumor marker that doctors monitor. Tumor markers, also called ...
Science Daily

Protein from pregnancy hormone may prevent breast cancer

Researchers have found that hormones produced during pregnancy induce a protein that directly inhibits the growth of breast cancer. This protein, alpha-fetoprotein, may serve as a viable, ...
Medscape

AFP Predicts Outcome If Liver Cancer Recurs Posttransplant

May 19, 2011 (Philadelphia, Pennsylvania) — A low serum albumin or high alpha-fetoprotein (AFP) level independently predicted mortality when hepatocellular carcinoma (HCC) recurred after liver ...
Business Wire

Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on ...
AFP

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, presented results from the Phase 1b dose escalation of the TheraPb Phase 1/2 clinical ...
AFP

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) ...